Thanks Dew. Just wondering how you now see Anadys as an investment, in light of today's clinical data? Their 2008 year end cash level is in the $25-27 mil range (as per today's conf call), and the CEO indicated they've been in partnering discussions with multiple parties for the Hep C program since Fall '08. Market cap now just over $100 mil. Any thoughts on additional nearterm upside vrs a pullback? Thanks for any insights.
Market Data 
Markets 
AI
